Damon Runyon Fellow Elise C. Jeffery, PhD, from the University of Texas Southwestern Medical Center

A few weeks ago I had the opportunity to attend a dinner with prospective donors at the beautiful new home of Damon Runyon Cancer Research Foundation board member Cindy Sulzberger in West Palm Beach, Florida. Cindy invited several of her friends to the gathering, and they were all eager to hear about the work of Damon Runyon scientists, and the goals of the foundation. As I described my work to the group during dinner, I was impressed by their interest in cancer research. They had a number of good questions such as, “Will we ever find a silver bullet cure?” and “How much progress could be made if we spent an amount equal to the defense budget on cancer research?” Although these questions have no easy answer, they reflect the thoughts of those in the community who have been affected by this disease. ​

Three Damon Runyon scientists received 2017 Pershing Square Sohn Prizes for Young Investigators in Cancer Research. Recipients receive $200,000 per year for up to three years and opportunities to present their work to scientific and business audiences, helping to bridge the gap between the academic and business communities. This year, three of the six awards were granted to Damon Runyon scientists:  

Yimon Aye, PhD (Damon Runyon Fellow ’09 – ’12), Weil Cornell Medicine, New York

Daniel A. Heller, PhD (Damon Runyon Fellow ‘10 – ’12), Memorial Sloan Kettering Cancer Center, New York

Eirini P. Papapetrou, MD, PhD (Damon Runyon-Rachleff Innovator ’14 – ’17), Icahn School of Medicine at Mount Sinai, New York

C. Ryan Miller, MD, PhD (Damon Runyon Clinical Investigator ’09-’12) of the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, and colleagues, reported two studies on the genetics underlying brain tumors. The first study showed that mutations in MAPK and PI3K affect how cancer starts in glial cells, brain cells that provide support and insulation for neurons. These mutations triggered tumor initiation and produced increasingly dense low-grade gliomas that quickly progressed to aggressive and often deadly glioblastoma (GBM).

Election to the National Academy of Sciences is one of the highest honors that can be earned by a U.S. scientist.  In recognition of their distinguished and continuing achievements in biomedical research, members of the Damon Runyon community of scientists were inducted this month:  

Ardem Patapoutian, PhD (Damon Runyon Scholar ’03-‘05, Fellow ’96-‘99), Scripps Research Institute, La Jolla

Guillermina Lozano, PhD (Former Fellowship Award Committee Member), M.D. Anderson Cancer Center, Houston

May is National Cancer Research Month and we are ‘Celebrating Scientists’ who are working to cure, treat and prevent this deadly disease. Throughout the month we will introduce you to some of the brilliant Damon Runyon scientists who are pursuing innovative cancer research.

The following Op Ed by Ralph J. DeBerardinis, MD, PhD, a Damon Runyon Clinical Investigator, appeared in the Philadelphia Inquirer on April 14, 2017

THE WHITE HOUSE recently proposed slashing support to the National Institutes of Health, the federal agency funding thousands of health-related research projects in the United States. I direct a clinic and research laboratory developing cures for cancer and childhood genetic diseases. My lab runs on NIH funds, and I'm writing to outline why these cuts will be disastrous for our long-term prospects for health.

By Peter J. Turnbaugh, Damon-Runyon Innovator

For our 70^th Anniversary Annual Report, we recently asked some of our current award recipients how cancer will be prevented, diagnosed, and/or treated differently in the future. What can a future cancer patient, say 10-20 years from now, expect to experience? Their responses were fascinating, and over the next few months we will share their visions for the future on this blog.

Cancer is notoriously hard to treat due to the severity of side effects and the high rate of relapse. While one patient may show a miraculous recovery, the next may show very little response or have an adverse drug outcome. Polymorphisms in the human genome are important, but they can fail to explain most of the observed variation in treatment outcomes. Far less attention has been paid to our “second genome”, the microbiome—comprising the trillions of microbes that thrive in and on the human body.

Feng Zhang, PhD (Damon Runyon-Rachleff Innovator ’12-’14) and colleagues at the Broad Institute, Cambridge, have developed a new CRISPR-based genetic diagnostic tool that may make it faster, less expensive, and easier to diagnose acute and chronic diseases like Zika, Ebola, cancer, and other hereditary disorders. The new tool dubbed SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) can detect extremely low concentrations of Zika virus and cancer DNA in blood, urine, and saliva samples.

Shruti Naik, PhD, Damon Runyon Fellow, Rockefeller University 

I was recently asked by Lorraine Egan to serve on a panel for women in STEM at her daughter’s school. The girls’ enthusiasm and curiosity for science was unmistakable. “How do you design an experiment?”, “What do you like about research?”, “How do you identify mentors?”. Their ardent inquiries were nothing but reassuring. I thought, “If these girls represent the future, then the future of women in science is secure!” Enjoying this blissful moment I walked back to my research institute and was promptly jolted back to reality.

Jedd D. Wolchok, MD, PhD (Damon Runyon-Lilly Clinical Investigator ‘03-‘08) at Memorial Sloan Kettering Cancer Center, New York, and colleagues, reported that matching the size of a tumor to the body's immune response could help doctors tailor immunotherapy treatments for melanoma patients whose disease has spread.